{"database": "openregs", "table": "documents", "rows": [["FDA-2014-D-1891-0001", "FDA", "FDA-2014-D-1891", "How To Obtain a Letter From the Food and Drug Administration Stating That Bioequivalence Study Protocols Contain Safety Protections\nComparable to Applicable Risk Evaluation and Mitigation Strategies\nfor Reference Listed Drugs; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2014-12-05T05:00:00Z", 2014, 12, "2014-12-05T05:00:00Z", "2015-02-04T04:59:59Z", "2020-04-23T19:23:52Z", "2014-28540", 0, 0, "090000648195e613"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2014-D-1891-0001"], "units": {}, "query_ms": 30.69067490287125, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}